To the full analysis
Buyback calculator for Torrent Pharmaceuticals
Torrent Pharmaceuticals stock: key metrics
TORNTPHARM.NSTorrent Pharmaceuticals had an operating margin of 24.8% and a return on invested capital (ROIC) of 12.8% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 91.7% | 9.6% | 7.2% |
| 2008 | 77.5% | 12.5% | 9.9% |
| 2009 | 80.7% | 13.5% | 11.3% |
| 2010 | 88.7% | 19.8% | 12.6% |
| 2011 | 78.2% | 16.0% | 12.8% |
| 2012 | 82.4% | 17.0% | 11.0% |
| 2013 | 88.8% | 20.5% | 14.2% |
| 2014 | 91.5% | 23.6% | 16.5% |
| 2015 | 85.9% | 18.1% | 16.4% |
| 2016 | 113.5% | 38.8% | 26.6% |
| 2017 | 85.8% | 19.1% | 16.5% |
| 2018 | 85.6% | 16.1% | 11.6% |
| 2019 | 87.2% | 18.3% | 5.8% |
| 2020 | 90.6% | 19.5% | 13.2% |
| 2021 | 71.7% | 23.1% | 15.9% |
| 2022 | 69.9% | 21.0% | 9.2% |
| 2023 | 70.1% | 22.6% | 13.2% |
| 2024 | 73.6% | 24.4% | 15.7% |
| 2025 | 74.5% | 25.9% | 16.9% |
| 2026 | 48.8% | 24.8% | 15.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 22.8% | 16.9% | 8.9% |
| 2008 | 26.4% | 23.3% | 10.6% |
| 2009 | 28.3% | 29.7% | 11.1% |
| 2010 | 27.8% | 30.3% | 11.8% |
| 2011 | 26.4% | 29.2% | 10.6% |
| 2012 | 23.8% | 37.7% | 9.2% |
| 2013 | 30.4% | 40.3% | 11.4% |
| 2014 | 34.9% | 42.7% | 13.1% |
| 2015 | 30.2% | 20.6% | 9.5% |
| 2016 | 51.1% | 42.9% | 19.2% |
| 2017 | 21.5% | 19.5% | 9.2% |
| 2018 | 14.7% | 9.2% | 4.8% |
| 2019 | 9.2% | 11.0% | 3.1% |
| 2020 | 21.2% | 13.4% | 7.3% |
| 2021 | 21.4% | 15.0% | 8.9% |
| 2022 | 13.1% | 11.6% | 5.9% |
| 2023 | 20.1% | 14.2% | 8.3% |
| 2024 | 24.2% | 17.5% | 11.0% |
| 2025 | 25.2% | 20.9% | 12.8% |
| 2026 | 25.8% | 12.8% | 4.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.